SVACF has agreed to acquire VBI to form a commercial-stage company with a licensed hepatitis B (“HBV”) vaccine and a pipeline of preventative and therapeutic vaccine candidates.http://biotechstocks.com/svacf-agreement-to-acquire-abiv/